About West Pharmaceutical Services (NYSE:WST)
West Pharmaceutical Services, Inc. manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, and washing and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including CZ, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as specialized testing services for drug packaging, devices, and administration systems. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Industry, Sector and Symbol
Industry Fabricated rubber products, not elsewhere classified
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNYSE:WST
CUSIP95530610
Phone610-594-2900
Debt
Debt-to-Equity Ratio0.15%
Current Ratio2.66%
Quick Ratio1.89%
Price-To-Earnings
Trailing P/E Ratio33.09
Forward P/E Ratio30.99
P/E Growth2.83
Sales & Book Value
Annual Sales$1.60 billion
Price / Sales4.07
Cash Flow$3.9595 per share
Price / Cash22.23
Book Value$17.24 per share
Price / Book5.11
Profitability
EPS (Most Recent Fiscal Year)$2.78
Net Income$150.70 million
Net Margins9.42%
Return on Equity14.68%
Return on Assets9.97%
Miscellaneous
Employees7,500
Outstanding Shares73,990,000
West Pharmaceutical Services (NYSE:WST) Frequently Asked Questions
What is West Pharmaceutical Services' stock symbol?
West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."
How often does West Pharmaceutical Services pay dividends? What is the dividend yield for West Pharmaceutical Services?
West Pharmaceutical Services declared a quarterly dividend on Thursday, February 15th. Shareholders of record on Wednesday, April 18th will be given a dividend of $0.14 per share on Wednesday, May 2nd. This represents a $0.56 annualized dividend and a yield of 0.64%. The ex-dividend date of this dividend is Tuesday, April 17th. View West Pharmaceutical Services' Dividend History.
How will West Pharmaceutical Services' stock buyback program work?
West Pharmaceutical Services declared that its Board of Directors has authorized a stock buyback program on Thursday, February 15th 2018, which authorizes the company to buyback 800,000 outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Stock buyback programs are often an indication that the company's management believes its shares are undervalued.
How were West Pharmaceutical Services' earnings last quarter?
West Pharmaceutical Services (NYSE:WST) announced its earnings results on Thursday, February, 15th. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.02. The medical instruments supplier earned $415.60 million during the quarter, compared to the consensus estimate of $416.90 million. West Pharmaceutical Services had a return on equity of 14.68% and a net margin of 9.42%. West Pharmaceutical Services's revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.54 EPS. View West Pharmaceutical Services' Earnings History.
When is West Pharmaceutical Services' next earnings date?
What guidance has West Pharmaceutical Services issued on next quarter's earnings?
West Pharmaceutical Services issued an update on its FY18 earnings guidance on Thursday, February, 15th. The company provided earnings per share (EPS) guidance of $2.80-2.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.90. The company issued revenue guidance of $1.72-1.73 billion, compared to the consensus revenue estimate of $1.73 billion.
What price target have analysts set for WST?
5 analysts have issued 12-month target prices for West Pharmaceutical Services' shares. Their forecasts range from $85.00 to $115.00. On average, they anticipate West Pharmaceutical Services' share price to reach $104.20 in the next twelve months. View Analyst Ratings for West Pharmaceutical Services.
Who are some of West Pharmaceutical Services' key competitors?
Some companies that are related to West Pharmaceutical Services include Fresenius Medical Care (FME), Alexion Pharmaceuticals (ALXN), Zimmer Biomet (ZBH), Mylan (MYL), Terumo (TRUMY), AmerisourceBergen (ABC), Align Technology (ALGN), Eisai (ESALY), Cardinal Health (CAH), Cerner (CERN), Centene (CNC), Sunny Optical Technology (Group) (SNPTF), Lonza Group (LZAGY), Teva Pharmaceutical Industries (TEVA) and Sysmex (SSMXY).
Who are West Pharmaceutical Services' key executives?
West Pharmaceutical Services' management team includes the folowing people:
- Mr. Eric M. Green, Chief Exec. Officer, Pres and Director (Age 48)
- Mr. William J. Federici, Chief Financial Officer, Sr. VP and Treasurer (Age 58)
- Mr. George Lloyd Miller, Sr. VP, Gen. Counsel and Corp. Sec. (Age 63)
- Ms. Annette F. Favorite, Chief HR Officer and Sr. VP (Age 53)
- Ms. Karen A. Flynn, Chief Commercial Officer and Sr. VP (Age 55)
Has West Pharmaceutical Services been receiving favorable news coverage?
Media headlines about WST stock have been trending somewhat positive recently, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. West Pharmaceutical Services earned a coverage optimism score of 0.14 on Accern's scale. They also gave headlines about the medical instruments supplier an impact score of 45.49 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of West Pharmaceutical Services?
Shares of WST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is West Pharmaceutical Services' stock price today?
One share of WST stock can currently be purchased for approximately $88.02.
How big of a company is West Pharmaceutical Services?
West Pharmaceutical Services has a market capitalization of $6.81 billion and generates $1.60 billion in revenue each year. The medical instruments supplier earns $150.70 million in net income (profit) each year or $2.78 on an earnings per share basis. West Pharmaceutical Services employs 7,500 workers across the globe.
How can I contact West Pharmaceutical Services?
West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The medical instruments supplier can be reached via phone at 610-594-2900 or via email at [email protected]
MarketBeat Community Rating for West Pharmaceutical Services (WST)
MarketBeat's community ratings are surveys of what our community members think about West Pharmaceutical Services and other stocks. Vote "Outperform" if you believe WST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WST will underperform the S&P 500 over the long term. You may vote once every thirty days.
West Pharmaceutical Services (NYSE:WST) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for West Pharmaceutical Services in the last 12 months. Their average twelve-month price target is $104.20, suggesting that the stock has a possible upside of 18.38%. The high price target for WST is $115.00 and the low price target for WST is $85.00. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Buy |
| Consensus Rating Score: | 2.20 | 2.40 | 2.40 | 2.60 |
| Ratings Breakdown: | 1 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $104.20 | $106.80 | $106.80 | $106.00 |
| Price Target Upside: | 18.38% upside | 6.40% upside | 6.40% upside | 5.02% upside |
West Pharmaceutical Services (NYSE:WST) Consensus Price Target History
West Pharmaceutical Services (NYSE:WST) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
West Pharmaceutical Services (NYSE:WST) Dividend Information
West Pharmaceutical Services pays an annual dividend of $0.56 per share, with a dividend yield of 0.64%. WST's next quarterly dividend payment will be made on Wednesday, May 2. The company has grown its dividend for the last 25 consecutive years and is increasing its dividend by an average of 8.90% each year. West Pharmaceutical Services pays out 20.14% of its earnings out as a dividend.
| Next Dividend: | 5/2/2018 |
| Annual Dividend: | $0.56 |
| Dividend Yield: | 0.64% |
| Dividend Growth: | 8.90% (3 Year Average) |
| Payout Ratio: | 20.14% (Trailing 12 Months of Earnings)
19.72% (Based on This Year's Estimates)
17.28% (Based on Next Year's Estimates)
|
| Track Record: | 25 Years of Consecutive Dividend Growth |
| Frequency: | Quarterly Dividend |
West Pharmaceutical Services (NYSE:WST) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 2/15/2018 | Quarterly | $0.14 | | 4/17/2018 | 4/18/2018 | 5/2/2018 |
| 12/22/2017 | Quarterly | $0.14 | 0.56% | 1/17/2018 | 1/18/2018 | 2/1/2018 |
| 7/20/2017 | Quarterly | $0.14 | 0.6% | 10/17/2017 | 10/18/2017 | 11/1/2017 |
| 5/16/2017 | quarterly | $0.13 | 0.54% | 7/17/2017 | 7/19/2017 | 8/2/2017 |
| 2/16/2017 | Quarterly | $0.13 | | 4/17/2017 | 4/19/2017 | 5/3/2017 |
| 12/14/2016 | quarterly | $0.13 | 0.61% | 1/13/2017 | 1/18/2017 | 2/1/2017 |
| 9/12/2016 | quarterly | $0.13 | | 10/17/2016 | 10/19/2016 | 11/2/2016 |
| 7/6/2016 | Quarterly | $0.12 | | 7/18/2016 | 7/20/2016 | 8/3/2016 |
| 3/4/2016 | Quarterly | $0.12 | | 4/18/2016 | 4/20/2016 | 5/4/2016 |
| 12/17/2015 | Quarterly | $0.12 | | 1/15/2016 | 1/20/2016 | 2/3/2016 |
| 7/15/2015 | quarterly | $0.12 | 0.79% | 10/19/2015 | 10/21/2015 | 11/4/2015 |
| 7/2/2015 | quarterly | $0.11 | 0.76% | 7/20/2015 | 7/22/2015 | 8/5/2015 |
| 2/20/2015 | quarterly | $0.11 | 0.82% | 4/20/2015 | 4/22/2015 | 5/6/2015 |
| 12/22/2014 | quarterly | $0.11 | 0.81% | 1/16/2015 | 1/21/2015 | 2/4/2015 |
| 7/16/2014 | quarterly | $0.11 | | 10/20/2014 | 10/22/2014 | 11/5/2014 |
| 7/16/2014 | quarterly | $0.11 | 1.11% | 10/15/2014 | 10/19/2014 | 11/3/2014 |
| 5/8/2014 | quarterly | $0.10 | 0.94% | 7/21/2014 | 7/23/2014 | 8/6/2014 |
| 2/20/2014 | quarterly | $0.10 | 0.83% | 4/21/2014 | 4/23/2014 | 5/7/2014 |
| 12/19/2013 | quarterly | $0.10 | 0.81% | 1/17/2014 | 1/22/2014 | 2/5/2014 |
| 8/1/2013 | quarterly | $0.20 | | | 10/23/2013 | 11/6/2013 |
| 5/10/2013 | quarterly | $0.19 | 1.16% | 7/22/2013 | 7/24/2013 | 8/7/2013 |
| 3/15/2013 | quarterly | $0.19 | 1.21% | 4/15/2013 | 4/17/2013 | 5/1/2013 |
| 12/27/2012 | quarterly | $0.19 | 1.4% | 1/18/2013 | 1/23/2013 | 2/6/2013 |
(Data available from 1/1/2013 forward)
West Pharmaceutical Services (NYSE WST) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 94.34%
West Pharmaceutical Services (NYSE WST) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/8/2017 | William J Federici | CFO | Sell | 21,000 | $99.01 | $2,079,210.00 | 190,493 |  |
| 5/18/2017 | William J. Federici | CFO | Sell | 54,996 | $95.45 | $5,249,368.20 | | |
| 5/2/2017 | Daniel Malone | VP | Sell | 4,124 | $93.31 | $384,810.44 | | |
| 12/8/2016 | Patrick J. Zenner | Director | Buy | 332 | $84.53 | $28,063.96 | | |
| 10/31/2016 | Paula A. Johnson | Director | Sell | 2,466 | $75.87 | $187,095.42 | | |
| 9/6/2016 | Karen Flynn | SVP | Sell | 14,581 | $83.28 | $1,214,305.68 | 13,513 | |
| 8/23/2016 | Paula A Johnson | Director | Sell | 3,042 | $81.55 | $248,075.10 | 38,450 | |
| 6/2/2016 | Daniel Malone | VP | Sell | 3,950 | $74.95 | $296,052.50 | 30,666 | |
| 5/25/2016 | Thomas W Hofmann | Director | Sell | 2,466 | $73.57 | $181,423.62 | 34,506 | |
| 3/1/2016 | Michael A Anderson | VP | Sell | 16,414 | $63.58 | $1,043,602.12 | 70,507 | |
| 2/29/2016 | Thomas W Hofmann | Director | Sell | 3,042 | $62.70 | $190,733.40 | 34,637 | |
| 2/25/2016 | Heino Lennartz | Insider | Sell | 5,680 | $62.47 | $354,829.60 | 18,304 | |
| 2/24/2016 | Heino Lennartz | Insider | Sell | 19,658 | $59.45 | $1,168,668.10 | 20,911 | |
| 2/23/2016 | Paula A. Johnson | Director | Sell | 7,800 | $59.39 | $463,242.00 | | |
| 2/22/2016 | Warwick Bedwell | Insider | Sell | 16,042 | $59.52 | $954,819.84 | 43,623 | |
| 11/25/2015 | John E. Paproski | insider | Sell | 17,560 | $63.41 | $1,113,479.60 | 70,288 | |
| 11/12/2015 | Heino Lennartz | Insider | Sell | 3,500 | $61.87 | $216,545.00 | 15,435 | |
| 11/6/2015 | Michael A Anderson | VP | Sell | 3,000 | $62.18 | $186,540.00 | 61,497 | |
| 11/5/2015 | Michael A. Anderson | VP | Sell | 10,000 | $61.98 | $619,800.00 | 64,497 | |
| 11/4/2015 | Daniel Malone | VP | Sell | 4,456 | $61.65 | $274,712.40 | 22,627 | |
| 8/17/2015 | William J Federici | CFO | Sell | 52,678 | $59.72 | $3,145,930.16 | | |
| 5/28/2015 | Heino Lennartz | Insider | Sell | 9,584 | $55.00 | $527,120.00 | | |
| 5/22/2015 | Karen Flynn | Insider | Sell | 3,091 | $55.24 | $170,746.84 | | |
| 5/21/2015 | Eric Mark Green | CEO | Buy | 18,300 | $54.89 | $1,004,487.00 | | |
| 5/18/2015 | Karen Flynn | Insider | Sell | 1,909 | $55.00 | $104,995.00 | | |
| 5/15/2015 | Donald E Morel Jr | CEO | Sell | 20,000 | $54.29 | $1,085,800.00 | | |
| 2/27/2015 | Richard D Luzzi | VP | Sell | 10,000 | $54.85 | $548,500.00 | | |
| 2/26/2015 | Michael A Anderson | VP | Sell | 4,682 | $54.93 | $257,182.26 | | |
| 2/25/2015 | Heino Lennartz | Insider | Sell | 3,617 | $54.82 | $198,283.94 | | |
| 2/24/2015 | John E Paproski | Insider | Sell | 9,282 | $52.87 | $490,739.34 | | |
| 2/23/2015 | Heino Lennartz | Insider | Sell | 21,040 | $53.40 | $1,123,536.00 | | |
| 2/23/2015 | Patrick J Zenner | Director | Sell | 12,800 | $53.69 | $687,232.00 | | |
| 11/26/2014 | Richard D Luzzi | VP | Sell | 8,000 | $52.11 | $416,880.00 | | |
| 11/21/2014 | William J Federici | CFO | Sell | 3,000 | $51.22 | $153,660.00 | | |
| 11/20/2014 | Donald E Morel Jr | CEO | Sell | 20,000 | $51.30 | $1,026,000.00 | | |
| 11/13/2014 | John R Gailey | VP | Sell | 28,000 | $52.37 | $1,466,360.00 | | |
| 11/11/2014 | Michael A Anderson | VP | Sell | 4,600 | $51.73 | $237,958.00 | | |
| 11/10/2014 | Warwick Bedwell | Insider | Sell | 6,306 | $49.95 | $314,984.70 | | |
| 8/21/2014 | Richard D Luzzi | VP | Sell | 10,000 | $44.07 | $440,700.00 | | |
| 8/20/2014 | John R Gailey | VP | Sell | 20,000 | $43.96 | $879,200.00 | | |
| 8/19/2014 | Michael A Anderson | VP | Sell | 9,800 | $43.41 | $425,418.00 | | |
| 8/18/2014 | William J Federici | CFO | Sell | 38,366 | $42.56 | $1,632,856.96 | | |
| 8/13/2014 | Heino Lennartz | Insider | Sell | 7,555 | $39.65 | $299,555.75 | | |
| 8/11/2014 | Heino Lennartz | Insider | Sell | 11,445 | $40.00 | $457,800.00 | | |
| 8/7/2014 | John E Paproski | Insider | Sell | 14,000 | $40.44 | $566,160.00 | | |
| 5/30/2014 | Richard D Luzzi | VP | Sell | 22,828 | $42.17 | $962,656.76 | | |
| 5/29/2014 | Heino Lennartz | Insider | Sell | 2,000 | $43.00 | $86,000.00 | | |
| 2/28/2014 | Heino Lennartz | Insider | Sell | 16,044 | $45.84 | $735,456.96 | | |
| 2/26/2014 | Patrick J Zenner | Director | Sell | 12,800 | $46.12 | $590,336.00 | | |
| 2/24/2014 | Warwick Bedwell | Insider | Sell | 24,606 | $47.49 | $1,168,538.94 | | |
| 11/26/2013 | Donald E Morel Jr | CEO | Sell | 35,000 | $48.60 | $1,701,000.00 | | |
| 11/22/2013 | William J Federici | CFO | Sell | 36,000 | $48.34 | $1,740,240.00 | | |
| 11/19/2013 | Karen Flynn | Insider | Sell | 5,500 | $47.75 | $262,625.00 | | |
| 11/8/2013 | Michael A Anderson | VP | Sell | 9,200 | $46.80 | $430,560.00 | | |
| 11/7/2013 | Heino Lennartz | Insider | Sell | 5,102 | $46.70 | $238,263.40 | | |
| 11/6/2013 | Michael A Anderson | VP | Sell | 6,000 | $46.53 | $279,180.00 | | |
| 11/5/2013 | John R Gailey | VP | Sell | 6,000 | $46.83 | $280,980.00 | | |
| 11/5/2013 | Warwick Bedwell | Insider | Sell | 6,304 | $46.84 | $295,279.36 | | |
| 11/4/2013 | Richard D Luzzi | VP | Sell | 38,708 | $46.99 | $1,818,888.92 | | |
| 8/30/2013 | Donald E Morel Jr | CEO | Sell | 10,000 | $74.46 | $744,600.00 | | |
| 8/27/2013 | John R Gailey | VP | Sell | 13,749 | $76.77 | $1,055,510.73 | | |
| 8/22/2013 | L Robert Johnson | Director | Sell | 1,883 | $76.81 | $144,633.23 | | |
| 8/14/2013 | John E Paproski | Insider | Sell | 6,011 | $79.08 | $475,349.88 | | |
| 8/12/2013 | Anthony Welters | Director | Sell | 19,200 | $78.43 | $1,505,856.00 | | |
| 8/8/2013 | Michael A Anderson | VP | Sell | 4,300 | $78.00 | $335,400.00 | | |
| 5/31/2013 | Michael A Anderson | VP | Sell | 4,000 | $68.94 | $275,760.00 | | |
| 5/28/2013 | Donald E Morel Jr | CEO | Sell | 10,000 | $67.87 | $678,700.00 | | |
| 5/24/2013 | L Robert Johnson | Director | Sell | 1,700 | $67.47 | $114,699.00 | | |
| 5/20/2013 | John R Gailey | VP | Sell | 9,282 | $68.54 | $636,188.28 | | |
| 5/17/2013 | L Robert Johnson | Director | Sell | 4,000 | $67.80 | $271,200.00 | | |
| 5/8/2013 | L Robert Johnson | Director | Sell | 6,400 | $64.49 | $412,736.00 | | |
(Data available from 1/1/2013 forward)
West Pharmaceutical Services (NYSE WST) News Headlines
| Source: |
|
West Pharmaceutical Services (NYSE:WST) SEC Filings
This page is loading this company's SEC Filings. Please wait...
West Pharmaceutical Services (NYSE:WST) Income Statement, Balance Sheet and Cash Flow Statement
West Pharmaceutical Services (NYSE WST) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
